Ohr Pharmaceutical has expanded its Scientific Advisory Board (SAB) with the addition of two prominent ophthalmologists who will join the current panel of retinal ophthalmology experts focused on advancing the company’s Squalamine eye drop program into clinical efficacy trials. David S. Boyer, M.D. of Retina-Vitreous Associates Medical Group in Los Angeles and Lawrence J. Singerman, [...]